Work

Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson’s disease

Year: 2025

Type: article

Source: Cell stem cell

DOI: 10.1016/j.stem.2025.01.006

Authors: Jeha Jeon, Young Cha, Yean Ju Hong, In-Hee Lee, Heejin Jang, Sanghyeok Ko, Serhiy Naumenko, Minseon Kim, Hannah L. Ryu, Zenith Shrestha, Nayeon Lee, Tae-Yoon Park, HoeWon Park, Seo-Hyun Kim, Ki-Jun Yoon, Bin Song, Jeffrey Schweitzer, Todd M. Herrington, Sek Won Kong, Bob Carter, Pierre Leblanc, Kwang-Soo Kim

Institutions: Harvard University, McLean Hospital, Boston Children's Hospital, Korea Advanced Institute of Science and Technology, Massachusetts General Hospital, Harvard Stem Cell Institute

Language: English

Topic: Pluripotent Stem Cells Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Massachusetts General Hospital, McLean Hospital, National Institutes of Health, National Institute of Neurological Disorders and Stroke

Awards: Crosstalk between Nurr1 and risk factors of Parkinson's disease and its regulation by Nurr1's ligands, G2738768939, Using phasic stimulation to explore the subthalamic nucleus - cortical decision-making network in Parkinson's disease, G5595284252, Crosstalk Between Nurr1 and Risk Factors of Parkinson's Disease and its Regulation by Nurr1's Ligands, Human iPSC-Based Personalized Cell Therapy of PD

OpenAlex ID: W4407481743

FWCI: 10.77

Cites: 52

Cited by: 39

Related to: 10